Circulating Levels of MicroRNAs in Hypertrophic Cardiomyopathy: The Relationship With Left Ventricular Hypertrophy, Left Atrial Dilatation and Ventricular Depolarisation-Repolarisation Parameters

• Published in: Heart, lung & circulation Vol. 31; no. 2; pp. 199 - 206
• Main Authors: Sonsöz, Mehmet Rasih, Yilmaz, Mustafa, Cevik, Erdem, Orta, Huseyin, Bilge, Ahmet Kaya, Elitok, Ali, Onur, Imran, Komurcu-Bayrak, Evrim
• Format: Journal Article
• Language: English
• Published: Australia Elsevier B.V 01.02.2022
• Subjects: Cardiomyopathy, Hypertrophic - diagnosis; Cardiomyopathy, Hypertrophic - genetics; Circulating MicroRNA - genetics; Dilatation; Echocardiography; Electrocardiography; Fibrosis; Humans; Hypertrophic cardiomyopathy; Hypertrophy, Left Ventricular - diagnosis; Hypertrophy, Left Ventricular - genetics; MicroRNA; MicroRNAs; Electrocardiography; Hypertrophic cardiomyopathy; Echocardiography; MicroRNA
• DOI: 10.1016/j.hlc.2021.04.019
• ISSN: 1443-9506

MicroRNAs are small, endogenous, non-coding RNAs that regulate the expression of many genes. It has recently been shown that circulating microRNAs may be biomarkers of hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy (HCM). To determine whether circulating levels of microRNAs involved in HCM are associated with electrocardiographic and echocardiographic parameters. This study enrolled 20 patients with familial HCM and 20 blood donors. Peripheral serum levels of miR-29a-3p, miR-199a-5p and miR-451a were assessed by quantitative real-time polymerase chain reaction and compared with levels in the control group. Whether circulating levels of miRNAs in HCM patients correlated with electrocardiographic and echocardiographic parameters was also assessed. Median circulating levels of miR-29a and miR-451a were significantly higher in HCM than the control group. Median miR-199a levels did not differ between groups. However, circulating levels of miR-199a negatively correlated with corrected QT duration (Bazett formula). Median miR-29a levels positively correlated with QRS duration. In addition, circulating levels of miR-29a correlated with maximal wall thickness, left ventricular mass index and left atrial volume index. The data suggested that serum levels of miR-29a and miR-451a were significantly increased in HCM patients. As the circulating level of miR-29a correlated with QRS duration, left ventricular hypertrophy and left atrial dilatation, the serum miR-199a level negatively correlated with corrected QT duration. These miRNAs may be seen as potential biomarkers for further research in HCM pathophysiology.